Characterization of brain-penetrant pyrimidine-containing molecules with differential microtubule-stabilizing activities developed as potential therapeutic agents for Alzheimer's disease and related tauopathies

Journal of Pharmacology and Experimental Therapeutics

Volumn 357, Issue 2, 2016, Pages 432-450

  Kovalevich, Jane ^a   Cornec, Anne Sophie ^a,b   Yao, Yuemang ^a   James, Michael ^a   Crowe, Alexander ^b   Lee, Virginia M Y ^a   John, Trojanowski Q ^a   Smith, Amos B ^b   Ballatore, Carlo ^b   Brunden, Kurt R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TUBULIN; BETA TUBULIN; CDR 51597; CEVIPABULIN; CHLOROQUINE; CNDR 51539; CNDR 51549; CNDR 51554; CNDR 51555; CNDR 51567; CNDR 51647; CNDR 51655; CNDR 51657; EPOTHILONE D; PHENYLPYRIMIDINE; PROTEASOME; PYRIMIDINE DERIVATIVE; TAU PROTEIN; TRIAZOLOPYRIMIDINE; TUBULIN; UNCLASSIFIED DRUG; HALOGENATED HYDROCARBON; TRIAZOLE DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CELL ASSAY; CELL DIVISION; CELL INCLUSION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DOSE COMPARISON; DRUG PENETRATION; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; MALE; MICROTUBULE; MOUSE; NERVE CELL; NERVE CELL CULTURE; NERVE DEGENERATION; NERVE FIBER TRANSPORT; NEUROFIBRILLARY TANGLE; NONHUMAN; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; TAUOPATHY; ANIMAL; BIOAVAILABILITY; BLOOD BRAIN BARRIER; DOSE RESPONSE; DRUG EFFECTS; GENETICS; METABOLISM; TAUOPATHIES;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL AVAILABILITY; BLOOD-BRAIN BARRIER; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HYDROCARBONS, HALOGENATED; MALE; MICE; MICROTUBULES; NEURONS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRIMIDINES; TAU PROTEINS; TAUOPATHIES; TRIAZOLES; TUBULIN;

EID: 85011973296     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.115.231175     Document Type: Article

References (52)

1. Alonso AC, Zaidi T, Grundke-Iqbal I, and Iqbal K (1994) Role of abnormally phos-phorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci USA 91:5562-5566.
2. Alonso AD, Grundke-Iqbal I, Barra HS, and Iqbal K (1997) Abnormal phosphoryla-tion of tau and the mechanism of Alzheimer neurofibrillary degeneration: se-questration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc Natl Acad Sci USA 94:298-303.
3. Arriagada PV, Growdon JH, Hedley-Whyte ET, and Hyman BT (1992) Neurofibril-lary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42:631-639.
4. Baird FJ and Bennett CL (2013) Microtubule defects & neurodegeneration. J Genet Syndr Gene Ther 4:203.
5. Ballatore C, Brunden KR, Huryn DM, Trojanowski JQ, Lee VMY, and Smith AB, 3rd (2012) Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies. J Med Chem 55:8979-8996.
6. Ballatore C, Lee VM, and Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8:663-672.
7. Barten DM, Fanara P, Andorfer C, Hoque N, Wong PYA, Husted KH, Cadelina GW, Decarr LB, Yang L, and Liu V, et al. (2012) Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027. J Neurosci 32:7137-7145.
8. Beyer CF, Zhang N, Hernandez R, Vitale D, Lucas J, Nguyen T, Discafani C, Ayral-Kaloustian S, and Gibbons JJ (2008) TTI-237: a novel microtubule-active compound with in vivo antitumor activity. Cancer Res 68:2292-2300.
9. Beyer CF, Zhang N, Hernandez R, Vitale D, Nguyen T, Ayral-Kaloustian S, and Gibbons JJ (2009) The microtubule-active antitumor compound TTI-237 has both paclitaxel-like and vincristine-like properties. Cancer Chemother Pharmacol 64:681-689.
10. Bialojan C and Takai A (1988) Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics. Biochem J 256:283-290.
11. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, Goetz M, Lazarides E, and Woods CM (1995) Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55:2325-2333.
12. Brunden KR, Ballatore C, Lee VM, Smith AB, 3rd, and Trojanowski JQ (2012) Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. Biochem Soc Trans 40:661-666.
13. Brunden KR, Trojanowski JQ, and Lee VMY (2009) Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 8: 783-793.
14. Brunden KR, Yao Y, Potuzak JS, Ferrer NI, Ballatore C, James MJ, Hogan AM, Trojanowski JQ, Smith AB, 3rd, and Lee VM (2011) The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies. Pharmacol Res 63:341-351.
15. Brunden KR, Zhang B, Carroll J, Yao Y, Potuzak JS, Hogan AML, Iba M, James MJ, Xie SX, and Ballatore C, et al. (2010) Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J Neu-rosci 30:13861-13866.
16. Cash AD, Aliev G, Siedlak SL, Nunomura A, Fujioka H, Zhu X, Raina AK, Vinters HV, Tabaton M, and Johnson AB, et al. (2003) Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am J Pathol 162:1623-1627.
17. Cornec AS, James MJ, Kovalevich J, Trojanowski JQ, Lee VM, Smith AB, 3rd, Ballatore C, and Brunden KR (2015) Pharmacokinetic, pharmacodynamic and metabolic characterization of a brain retentive microtubule (MT)-stabilizing tri-azolopyrimidine. Bioorg Med Chem Lett 25:4980-4982.
18. Das V and Miller JH (2012) Microtubule stabilization by peloruside A and paclitaxel rescues degenerating neurons from okadaic acid-induced tau phosphorylation. Eur J Neurosci 35:1705-1717.
19. Dawson HN, Cantillana V, Jansen M, Wang H, Vitek MP, Wilcock DM, Lynch JR, and Laskowitz DT (2010) Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease. Neuroscience 169:516-531.
20. Dawson HN, Ferreira A, Eyster MV, Ghoshal N, Binder LI, and Vitek MP (2001) Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J Cell Sci 114:1179-1187.
21. Demasi M and Davies KJ (2003) Proteasome inhibitors induce intracellular protein aggregation and cell death by an oxygen-dependent mechanism. FEBS Lett 542:89-94.
22. Gómez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, and Hyman BT (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 41:17-24.
23. Harada A, Oguchi K, Okabe S, Kuno J, Terada S, Ohshima T, Sato-Yoshitake R, Takei Y, Noda T, and Hirokawa N (1994) Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature 369:488-491.
24. Hempen B and Brion JP (1996) Reduction of acetylated alpha-tubulin immunoreac-tivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease. J Neuro-pathol Exp Neurol 55:964-972.
25. Huff LM, Sackett DL, Poruchynsky MS, and Fojo T (2010) Microtubule-disrupting chemotherapeutics result in enhanced proteasome-mediated degradation and disappearance of tubulin in neural cells. Cancer Res 70:5870-5879.
26. Joshi HC and Cleveland DW (1989) Differential utilization of beta-tubulin isotypes in differentiating neurites. J Cell Biol 109:663-673.
27. Katsetos CD, Reginato MJ, Baas PW, D'Agostino L, Legido A, Tuszyn Ski JA, Dráberová E, and Dráber P (2015) Emerging microtubule targets in glioma therapy. Semin Pediatr Neurol 22:49-72.
28. Kreis TE (1987) Microtubules containing detyrosinated tubulin are less dynamic. EMBO J 6:2597-2606.
29. Lecker SH, Goldberg AL, and Mitch WE (2006) Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol 17: 1807-1819.
30. Lee CB, Wu Z, Zhang F, Chappell MD, Stachel SJ, Chou TC, Guan Y, and Danishefsky SJ (2001a) Insights into long-range structural effects on the stereochemistry of aldol condensations: a practical total synthesis of desoxy-epothilone F. J Am Chem Soc 123:5249-5259.
31. Lee VM, Brunden KR, Hutton M, and Trojanowski JQ (2011) Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb Perspect Med 1:a006437.
32. Lee VM, Goedert M, and Trojanowski JQ (2001b) Neurodegenerative tauopathies. Annu Rev Neurosci 24:1121-1159.
33. Lopes S, Lopes A, Pinto V, Guimarães MR, Sardinha VM, Duarte-Silva S, Pinheiro S, Pizarro J, Oliveira JF, and Sousa N, et al. (2016) Absence of Tau triggers age-dependent sciatic nerve morphofunctional deficits and motor impairment. Aging Cell 15:208-216.
34. Lou K, Yao Y, Hoye AT, James MJ, Cornec AS, Hyde E, Gay B, Lee VM, Trojanowski JQ, and Smith AB, 3rd, et al. (2014) Brain-penetrant, orally bioavailable microtubule-stabilizing small molecules are potential candidate therapeutics for Alzheimer's disease and related tauopathies. J Med Chem 57: 6116-6127.
35. Merrick SE, Trojanowski JQ, and Lee VMY (1997) Selective destruction of stable microtubules and axons by inhibitors of protein serine/threonine phosphatases in cultured human neurons. J Neurosci 17:5726-5737.
36. Mi L, Gan N, Cheema A, Dakshanamurthy S, Wang X, Yang DC, and Chung FL (2009a) Cancer preventive isothiocyanates induce selective degradation of cellular alpha-and beta-tubulins by proteasomes. J Biol Chem 284: 17039-17051.
37. Mi L, Gan N, and Chung FL (2009b) Aggresome-like structure induced by iso-thiocyanates is novel proteasome-dependent degradation machinery. Biochem Biophys Res Commun 388:456-462.
38. Mizushima N and Komatsu M (2011) Autophagy: renovation of cells and tissues. Cell 147:728-741.
39. Rivkin A, Yoshimura F, Gabarda AE, Cho YS, Chou TC, Dong H, and Danishefsky SJ (2004) Discovery of (E)-9, 10-dehydroepothilones through chemical synthesis: on the emergence of 26-trifluoro-(E)-9, 10-dehydro-12, 13-desoxyepothilone B as a promising anticancer drug candidate. J Am Chem Soc 126:10913-10922.
40. Schiff PB and Horwitz SB (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77:1561-1565.
41. Schulze E, Asai DJ, Bulinski JC, and Kirschner M (1987) Posttranslational modification and microtubule stability. J Cell Biol 105:2167-2177.
42. van Tellingen O, Yetkin-Arik B, de Gooijer MC, Wesseling P, Wurdinger T, and de Vries HE (2015) Overcoming the blood-brain tumor barrier for effective glioblas-toma treatment. Drug Resist Updat 19:1-12.
43. Wibo M and Poole B (1974) Protein degradation in cultured cells. II. The uptake of chloroquine by rat fibroblasts and the inhibition of cellular protein degradation and cathepsin B1. J Cell Biol 63:430-440.
44. Wilcock GK and Esiri MM (1982) Plaques, tangles and dementia. A quantitative study. J Neurol Sci 56:343-356.
45. Wood JG, Mirra SS, Pollock NJ, and Binder LI (1986) Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau). Proc Natl Acad Sci USA 83:4040-4043.
46. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, and Lee VMY (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53: 337-351.
47. Yoshiyama Y, Lee VM, and Trojanowski JQ (2013) Therapeutic strategies for tau mediated neurodegeneration. J Neurol Neurosurg Psychiatry 84: 784-795.
48. Zhang B, Carroll J, Trojanowski JQ, Yao Y, Iba M, Potuzak JS, Hogan AM, Xie SX, Ballatore C, and Smith AB, 3rd, et al. (2012) The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci 32:3601-3611.
49. Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, Bruce J, Lee EB, Xie SX, Joyce S, and Li C, et al. (2005) Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci USA 102:227-231.
50. Zhang F, Su B, Wang C, Siedlak SL, Mondragon-Rodriguez S, Lee HG, Wang X, Perry G, and Zhu X (2015) Posttranslational modifications of a-tubulin in Alzheimer disease. Transl Neurodegener 4:9.
51. Zhang N, Ayral-Kaloustian S, Nguyen T, Afragola J, Hernandez R, Lucas J, Gibbons J, and Beyer C (2007) Synthesis and SAR of [1, 2, 4]triazolo[1, 5-a]pyrimidines, a class of anticancer agents with a unique mechanism of tubulin inhibition. J Med Chem 50:319-327.
52. Zhang N, Ayral-Kaloustian S, Nguyen T, Hernandez R, Lucas J, Discafani C, and Beyer C (2009) Synthesis and SAR of 6-chloro-4-fluoroalkylamino-2-heteroaryl-5-(substituted)phenylpyrimidines as anti-cancer agents. Bioorg Med Chem 17:111-118.